Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis

Neurology

Volumn 48, Issue 4, 1997, Pages 817-821

  Schwid, S R ^a,c   Petrie, M D ^a   McDermott, M P ^a   Tierney, D S ^b   Mason, D H ^b   Goodman, A D ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Elan Pharmaceutical Research Corporation   (United States)

^c Box 605 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE;

ADULT; ARTICLE; CLIMBING; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GRIP STRENGTH; HUMAN; INSOMNIA; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE CONTRACTION; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; SUSTAINED RELEASE FORMULATION; VERTIGO;

EID: 0030989459     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.4.817     Document Type: Article

References (23)

1. Waxman SG. Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 1982;306:1529-1533.
2. Sherrat RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibers. Nature 1980;283:570-572.
3. Bostock H, Sears TA, Sheratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibers. J Physiol (Lond.) 1981;313:301-315.
4. Targ EF, Kocsis JD. 4-aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985; 328:358-361.
5. Jones RE, Heron JR, Foster RS, et al. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983;60:353-362.
6. Stefoski D, Davis FA, Faut M, Schauf CL. 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987; 21:71-77.
7. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27:186-192.
8. Stefoski D, Davis FA, Fitzsimmons WE, et al. 4-aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991;41:1344-1348.
9. Bever CT, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994;44:1054-1059.
10. van Diemen HAM, Polman CH, van Dongen TMMM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, crossover study. Ann Neurol 1992;32:123-130.
11. Murray NMF, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981;31:264-277.
12. Amato MP, Fratiglione L, Groppi C, Siracuse G, Amaducci L. Interrater reliability in assessing functional systems and disability on the Kurtzke Scale in multiple sclerosis. Arch Neurol 1989;45:746-748.
13. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC, Canadian Cooperative MS Study Group. Interrater variability with Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis trial. Neurology 1990;40:971-975.
14. Francis DA, Bain P, Swan AV, Hughes AC. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol 1991;48:299-301.
15. Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337: 441-446.
16. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for MS: guidelines for research protocols. Ann Neurol 1983;13:227-231.
17. Personius KE, Pandya S, King WM, et al. FSH Dystrophy Natural History Study: standardization of testing procedure and reliability of measurements. The FSH DY Group. Phys Ther 1994;74:253-263.
18. The FSH-DY Group. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. Neurology 1997; 48:38-46.
19. Medical Research Council. Aids to the investigation of peripheral nerve injuries. London: Her Majesty's Stationery Office, 1976.
20. Senn S. Cross-over trials in clinical research. Chichester: Wiley, 1993.
21. Jones B, Kenward MG. Design and analysis of cross-over trials. London: Chapman and Hall, 1989.
22. Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972;28:577-584.
23. van Diemen HAM, Polman CH, Koetsier JC, et al. 4-aminopyridine in patients with multiple sclerosis: dosage and serum levels related to efficacy and safety. Clin Neuropharmacol 1993;16:195-204.